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Introduction:
Vitronectin, or S-protein, is a regulatory glycoprotein found in the circulation and
the extra-cellular matrix. It is known to be involved in a number of diverse physiological
processes including the immune response, cell adhesion, blood coagulation, and
fibrinolysis. There are few detailed studies involving the structure of vitronectin or how
its structure mediates the regulatory properties associated with the protein.

The

remainder of this introduction is intended to relate what is known about the structural
elements ofvitronectin and the role of the protein in vivo.
Physiological Importance:

The Immune Response-- Vitronectin was first isolated and characterized as a
component in the complement cascade of the immune response (1). It was named Sprotein, soluble protein, on account of its ability to associate with the terminal complexes
of the membrane attack complex and maintain these molecules in solution (1).
Furthermore, vitronectin was found to associate with the C9 molecule, possibly through
amino acid residues in the carboxyl terminal region of the protein, and prevent C9
polymerization (2). It is the C9 polymer that inserts into the cell membrane and forms the
lytic pore. Therefore, as it is understood, vitronectin prevents formation of the membrane
attack complex (2). This anti-cytolitic property is believed to function as a safeguard
mechanisn1, thus preventing injury to bystander cells (2).

Cell Adhesion-- Vitronectin has also been associated with the property of cell
adhesion and was subsequently characterized as "serum spreading factor (3,4)."
Vitronectin was found to be the major serum component in tissue culture media that was

responsible for cell adhesion (3,4). Vitronectin itself adheres to the surface of the culture
dish through non-covalent interactions (5). Upon adhesion of vitronectin to the surface
conformational changes occur (5).

It is believed that the tripeptide RGD, which is

recognized by the integrin class of cell receptors, becomes surface exposed during this
conformational change allowing for cell attachment (5).
Coagulation-- Vitronectin acts as a procoagulant through its neutralization of the

activity of the anticoagulation drug heparin (6-10).

Heparin accelerates the rate of

deactivation of a coagulation protease, thrombin, by a serine protease inhibitor,
antithrorrlbin, by supplying a surface on which these molecules can interact.
inactivation of thrombin by antithrombin is a diffusion limited process.

The

Heparin, a

glycosaminoglycan chain, binds both thrombin and antithrombin thus limiting their
diffusion to one dimension, that of the heparin chain, instead of the three dimensions
allowed in solution. Vitronectin destroys the catalytic property of heparin by binding to
the heparin chain and preventing the movement of thrombin and antithrombin along the
chain. The heparin binding site of vitronectin was localized to residues 340 through 379
by cyanogen bromide digestion (7).
Fibrinolysis--

Vitronectin is also known to be involved in the fibrinolytic

pathway (11, 12-16). Fibrinolysis is the degradation of blood clots. Blood clots are
formed when thrombin, the terminal protease of the coagulation cascade, cleaves soluble
fibrinogen into insoluble molecules of fibrin. The blood clot is composed mainly of this
fibrin.

During fibrinolysis, plasmin digests the clot into small soluble fragments.

Plasmin, however, must first be activated from its inactive form, plasminogen.
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Plasminogen is activated by a group of serine proteases called plasminogen activators.
Furthermore, these activator molecules can be inhibited by a molecule called
plasminogen activator inhibitor type one (PAl -1). PAl-1 is in a class of molecules called
serine protease inhibitors (SERPINS). These molecules have a common structure and
mode of inactivation of their target proteases.

SERPINS have a conserved "reactive

loop" that contains the bond that is a pseudosubstrate for the serine proteases. Instead of
cleaving this bond and releasing cleaved products, the protease forms a stable con1plex
with the inhibitor. For the SERPIN to effectively block the proteolytic activity of the
activators, however, the "reactive loop" must be surface exposed. In newly synthesized
PAl -1 the "reactive loop" is surfaced exposed, but quickly self inserts into central beta
sheet.

Upon insertion of the "reactive loop" into the beta sheet, PAI-l looses its

inhibitory activities and is said to become latent. Vitronectin plays an important antifibrinolytic role in this process by binding to active P AI-I and preventing the insertion of
the "reactive loop" into the core of the protein (17,18).

Structural Elements:
General Structure-- Mature vitronectin consists of 459 amino acids after the
cleavage of a 19 amino acid signal sequence that instructs the liver cells, where
vitronectin is synthesized, to secrete the protein into the circulation (19-23). The protein
is glycosylated and highly charged containing a large number of arginines and lysines.
Vitronectin also has nine tryptophan residues that can be used to monitor intrinsic protein
fluorescence. In addition, vitronectin contains 14 cysteines of which the oxidation states
are disputed. Vitronectin has a molecular weight of approximately 72 kilodaltons (24).
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The protein is believed to exist largely in a "closed" of folded form in the circulation and
as an "open" or unfolded form in the extra-cellular matrix. Moreover, vitronectin exists
as a single chain form (72 kD) and as a cleaved two chain form (62 kD + 10 kD) that is
disulfide cross-linked (19-23).
Primary Sequence--

Although no crystal structure has been resolved for

vitronectin much can be learned by analyzing the primary amino acid sequence of the
protein.

The 44 residues at the amino terminus of the protein comprise

"somatomedin B region."

the

This region of vitronectin has sequence homology with

another plasma protein, somatomedin B. Eight of the 14 cysteine residues in vitronectin
are in this region. Through the homology with somatomedin B, each of these cysteines is
believed to interact with one of the other seven cysteines contained within the region.
This forms what is essentially a "disulfide knot" (25).

Immediately adjacent to the

"somatomedin B region" is the RGD tripeptide associated with the integrin class of cell
receptors and the property of cell adhesion (5). Following the RGD sequence is an
"acidic domain" that has been postulated to interact with a basic region in the carboxyl
terminal region of the protein thus stabilizing the folded form of the vitronectin. This
hypothesis, however, was proposed on the basis of sequence analysis without any
experimental evidence (7).

After the "acidic region" are two "hemopexin repeats."

These regions have homology with the heme binding plasma protein, hemopexin (26).
The second of these homologous repeats is imperfect, interrupted by the "heparin binding
domain." The "heparin binding domain" is, of course, the region of the protein that binds
to heparin. This highly basic region is proposed to interact with the "acidic region" that

4

is more amino terminally located (7). At the carboxyl terminal edge of the "heparin
binding domain," after residue 379, is the endogenous cleavage site. Cleavage at this site,
by a trypsin-like protease, produces the 62 kD and 10 kD two chain fonn of the molecule
(27-28).
Effects of Denaturation Upon Structure-- It has been suggested that denaturation

of vitronectin, by heat or chemicals, results in the protein adopting a structure similar to
that of the molecule when it is in the extra-cellular matrix (1-5). Some

g~o.ups

argue that

vitronectin binds some ligands more tightly in this "open" confonnation (29-31), but this
observation is debatable.

Experimental evidence does suggest, however, that other

processes do occur upon denaturation (32). One phenomenon is the failure of folding and
unfolding curves to overlap as shown in the figure below. This historesis suggests that
the pathways of unfolding and refolding are quite different. This observation agrees with
the fact that upon removal of denaturant (or cooling if thermal denaturation) vitronectin
has a tendency to irreversibly self-associate into multimers with a molecular weight of
approximately 420 kilodaltons (24).

Formation of Multimers
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It has . also

been observed that disulfide rearrangement occurs

upon

denaturation (32). The SDS polyacrylamide gel below (cartoon) shows that non-reduced
native vitronectin migrates as a single band corresponding to both the single chain form
and two chain disulfide linked form.

Upon treatment of native vitronectin with a

reducing agent, dithiothreotol (DTT), the disulfide bonds are disrupted. On account of
the disruption of the disulfide bonds, including the one that links the 62 kD fragment and
the 10 kD fragment of the two chain form, vitronectin migrates as a doublet
;..,k ...

corresponding to the single chain form and the 62 kD fragment of the two chain form.
When vitronectin is denatured with urea, it migrates as a doublet even though no reducing
agent has been added to the protein. This illustrates the disruption of the disulfide bond
linking the large and small fragments of the two chain form, evidence that upon
denaturation, disulfide bond rearrangement occurs.
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Research Objective-- The primary objective of this study is to determine the

oxidation states of the cysteine residues in native and chemically altered vitronectin. An
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understanding of the oxidation states may be helpful in folding and binding studies, and
elucidating the disulfide bonded structure of the protein, which has not yet been
determined. A second goal is to attach a sulfhydryl specific fluorescent probe to the
protein that may be useful for monitoring protein/protein and protein/ligand interactions.

Materials and Methods:
Vitronectin was purified by a modification of the original procedure of Dahlback
and Podack, as described by Bittorf et al (33). The modifications of Bittorf et al. (33)
include addition of dithionotrobenzoic acid (DTNB) during the preparation to block free
sulfhydryls in the native protein that were originally reported in the Dahlback and Podack
purification (34).

Bittorf et al. indicate there is no clear evidence that DTNB is

maintained on vitronectin throughout the preparation, since reduction of the purified
protein sample with DTT was not accompanied by the release of the thionitrobenzoate
anion (33).

Purity of the protein was assessed by SDS-polyacrylamide gel

electrophoresis in the presence of p-mercaptoethanol. A molecular weight of 72 kD and
1

an extinction coefficient of 1.02 ml nlg- cm- I were used for the quantification of the final
purified vitronectin (24). Multimeric vitronectin was prepared by treating the protein
with 8 M urea at room temperature for two hours, followed by extensive dialysis into
phosphate buffer

(0.1 M sodium phosphate, 0.15 M sodium chloride, 1 mM EDTA, pH

7.5) to remove the denaturant.
Urea was purchased from ICN Biomedical.

Acrylodan was a product of

Molecular Probes Inc. Oxidized glutathione was from Calbiochem. Sephadex G-25 resin
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was purchased from Pharmacia Biotech. Both DTNB and DTT were from Sigma. All
other chemicals were of reagent grade quality.
Cysteine Oxidation State Determination-- The number of reduced cysteines in

vitronectin was determined using DTNB. The protein was denatured by adding 90 mg of
solid urea to 0.200 ml of vitronectin (1 mg mrl) in 20 mM Tris, 20 mM NaCI, 1mM
EDTA, pH 7.4, to give a final urea concentration of approximately 6 M.

After

dissolution of the denaturant, the reaction mixture was allowed to incubate at 25°C for 4
hours.

If reducing conditions were desired as well, 10 mM DTT was added to the

reaction nlixture prior to incubation.

If only reducing conditions were desired the

denaturant was omitted. Following the incubation period, urea and DTT were removed
by desalting the reaction mixture over a 5 ml Sephadex G-25 column equilibrated with
0.1 M acetate, pH 6.0. Eluted vitronectin (0.725 ml) was treated with 0.250/0 SDS for 5
minutes. The pH of the reaction mixture was then adjusted to 8.0 by the addition of
0.235 ml 2 M ammonium phosphate, pH 9.25. The resulting free sulfhydryls were then
reacted with 20 mM DTNB and the released thionitrobenzoate anion was quantitated at
412 nm using an extinction coefficient of 1.14 x 104 M- l cm- l (35).

Protein was

quantitated by absorption at 280 nm prior to the addition of DTNB using an extinction
coefficient of 1.02 ml mg- l cm- 1 (24). Quantitation of reduced cysteines in native protein
was determined in the same maimer, omitting the addition of urea and DTT to the
incubation mixture.
Fluorescent Labeling--

Labeling was performed by first partially reducing

vitronectin with mildly reducing conditions and then reacting the reduced protein with
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Acrylodan. Vitronectin was reduced by adding 0.2 nlM DTT to 0.200 ml of protein
(1 mg mrl) in 20 nlM Tris, 20 nlM NaCI, 1 mM EDTA, pH 7.4. This reaction mixture

was allowed to incubate for 30 minutes at 4°C. Following the incubation the reducing
agent was removed by desalting the mixture over a 5 ml Sephadex G-25 column
equilibrated with 0.1 M acetate, pH 6.0. The eluted protein (l ml) was then reacted with
20 mM Acrylodan in 0.1 % dimethyl formamide for 24 hours at 4°C in the dark with
gentle stirring. Unreacted probe was removed by centrifugation at 14,000 rpm for 10
minutes followed by desalting over a 5 ml sephadex G-25 column equilibrated with
20 mM Tris, 20 mM NaCI, 1 mM EDTA, pH 7.4. The success of the labeling was
determined by analysis of an emission spectrum from 400 nm to 600 nm when excited at
of 390 nm on a Perkin-Elmer LS-50B spectrofluorimeter. The stoichiometry of the
labeling was resolved from the ratio of the protein, determined by Bradford assay (BioRad kit), to that of the bound probe, determined spectrophotometricly at 390 nm with an
extinction coefficient of 2.00 x 104 M- 1 cm- 1 (36).

Results:
Cysteine Oxidation States-- Although vitronectin has been proposed to contain

cysteines in both the reduced sulfhydryl state and the oxidized disulfide state, the number
of free sulfhydryls has been disputed (33,34).

The number of reduced cysteines in

purified vitronectin were determined by treating the protein with DTNB under native and
chemically altered conditions.

Consistent with previous observations (33), native

vitronectin was found to have essentially no free sulfhydryls (see table). The reduced
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form, however, showed the presence of two free sulfhydryls. These results indicate that
native vitronectin does indeed contain a mixture of reduced and oxidized cysteine
residues. When vitronectin was treated with both denaturant and a strong oxidizing agent
(oxidized glutathione), however, only 0.43 cysteines were found to be free.

When

vitronectin was treated with varying concentrations of reducing agent, the maxinlum
number of sulfhydryls observed was 5.35, with a saturation at approximately 4 mM DTT
(see graph). Multimeric protein was analyzed in a similar manner, but only under native
and denaturing conditions. Multimeric protein was found to have 0.57 sulfhydryls when
untreated and 1.18 when denatured. This result clearly indicates the difference in the
oxidation states of cysteine residues in monomeric and multimeric vitronectin.

Number of free Cysteines

Sample
Native Vitronectin

None

Reduced Vitronectin (10 mM DTT)

5.25

Denatured Vitronectin

1.88

Denatured Vitronectin with 10 mM
Oxidized Glutathione

0.43

Untreated Multimeric Vitronectin

0.57

Denatured Multimeric Vitronectin

1.18

Reduced and Denatured Vitronectin

12.10
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The fully reduced and denatured vitronectin gave an average of 12.1 sulfhydryls per
molecule of the protein, in close agreement with the 14 cysteines expected from the
known sequence of the protein, validating the use ofDTNB for sulfhydryl quantitation.

Varying Concentrations of
Reducing Agents

.10

.so

1.00

1.50

2.00

2.50

Concmtration of Reducin& Agent (mM)

Fluorescent Labeling--

Acrylodan was used for labeling on account of its

sulfhydryl specificity and sensitivity towards environmental polarity (36).

When the

probe was reacted with untreated vitronectin no labeling was observed. This result was
not surprising since it had been shown ,by the DTNB studies that native vitronectin
contains no surface exposed free sulfhydryl groups. When vitronectin, however, was
reduced with 0.2 mM DTT prior to the addition of the Acrylodan, two molecules of probe
were incorporated per molecule of the protein.
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Discussion:
Cysteine Oxidation States-- It is apparent from the native and denaturing DTNB

reactions that vitronectin does indeed contain cysteines that are a mixture of reduced and
oxidized forms as suggested in the literature (34).

The native protein, as purified

following the Bittorf et al. protocol (33), has no free sulfhydryls that are surface exposed,
but does contain two that are buried within the core of the protein. These two sulfhydryls
become surface exposed, and thus available for reaction with DTNB, only after chemical
denaturant is added.

It is presumably these two reduced cysteines that initiate the

disulfide rearrangement upon denaturation as previously mentioned in the introduction of
this paper. These cysteines are sequestered within the core of the protein under native
conditions, but when the protein is denatured, they become labile. With the increased
motility permitted by denaturation, the free sulfhydryls are able to move close enough to
existing disulfides that a free sulfhydryl can attack a disulfide bond. This results in the
previously reduced cysteine becoming oxidized, forming a new disulfide bond, and the
disnlption of the formerly existing disulfide.

The severance of the disulfide also

generates a new reduced cysteine that can go through the same attacking process or
remain reduced. It has been reported that disulfide rearrangement can be prevented by
blocking the free sulfhydryls contained within the core of vitronectin (31). The results
obtained by reacting DruB with protein that had been denatured in the presence of
oxidized glutathione found that only 0.43 cysteines were reduced. This agrees with the
observations made by analyzing SDS-polyacrylamide gels that the addition of oxidizing
agent prevents disulfide rearrangement.
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It was noted earlier that reduction of cysteines with increasing concentrations of

reducing agent saturates at about 4 mM DTT. Only slightly over five cysteines could be
reduced regardless of the concentration of the reducing agent. Vitronectin contains an
even number of total cysteines and an even number of reduced cysteines in its native
conformation. It may seem confusing then, that an odd number of cysteines are produced
upon reduction, especially if one realizes that when one cysteine in a disulfide is reduced
the second cysteine in the disulfide must be reduced as well. One explanation for the
apparent reduction of an odd number of cysteines is a mixture of molecular species. It is
possible that the reduced vitronectin existed as two discrete populations, one population
with four free sulfhydryls and a second population with six free sulfhydryls. These two
populations, if they contained an equal or slightly skewed distribution of molecules,
would produce an average of five reduced cysteines when quantitated by the DTNB
reaction. A second explanation would be that five is the correct value. It is possible that
one of the two sulfhydryls buried within the protein became exposed when two disulfides
on the surface were reduced. This would allow the sulfhydryl that was buried in the
native protein to react with the DTNB. A final explanation for the apparent reduction of
an odd number of cysteines is that of experimental error. It is possible that the 5.25
reduced cysteines should have been six, or even four. The DTNB reaction, although very
precise, could simply not have been entirely accurate.
A final observation from the DTNB data regards the cysteine oxidation states of
the monomer versus the multi mer. It was found that the untreated monomer contains
essentially no free sulfhydryls while the denatured monomer contains about two reduced
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cysteines.

The untreated multimer, however, contained about 0.6 and the denatured

multimer about 1.2 free sulfhydryls per monomeric subunit of the multimer. Although
nothing can be postulated about which cysteine residues are differentially reduced in
these two forms of the protein, this data does help reinforce the observations that the
monomer and the individual subunits of the multimer are different species (24,31).

Fluorescent Labeling of Vitronectin-- Acrylodan was used as the fluorescent
probe in the labeling reactions due to its sulfhydryl specificity and its environmental
~,

.

sensitivity (36). Acrylodan forms a thio-ether with the protein through a carbonyl group
that stems from the central acryloyl rings. The probe is sensitive to the polarity of its
environment, showing a blue shift in the emission spectrum when in hydrophobic
environments and a red shift in hydrophilic environments. This may allow the probe to
be a useful tool in folding and binding studies.
When the probe was reacted with the protein and excited with 390 nm light, the
emission spectrunl from 400 nm to 600 nm showed an increase in fluorescent intensity
and an approximate 20 nm blue shift when compared to the same spectrum obtained from
free probe (see graph). The labeling under mildly reducing conditions incorporated two
molecules of the probe per molecule of vitronectin in agreement with the observation of
two reduced cysteines under the same reaction conditions.
Acrylodan Labeling
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Conclusion:
Oxidation States of the Cysteines--

The DTNB reactions were useful in

determining the number of free sulfhydryls in native and chemically altered vitronectin.
It was found that native monomeric vitronectin contained no free surface exposed

sulfhydryls, but had two free sulfhydryls buried within the core of the protein. These
sulfhydryls become exposed upon denaturation and initiate the sulfhydryl rearrangement
that is observed upon denaturation. These sulfhydryls, however, can be blocked by the
addition of oxidizing agent and the disulfide rearrangement prevented.
DTNB experiments were also used to analyze and compare the oxidation states of
the cysteines in monomeric and multimeric vitronectin. It was found that the oxidation
states of the two proteins consistently differed under denaturing and non-denaturing
conditions This is in agreement with the observation that the monomeric unit in these
two forms of the protein are structurally different (24,31).

Fluorescent Labeling-- It was found that vitronectin could be labeled with a
sulfhydryl specific probe, Acrylodan, only after the protein was partially reduced. The
reduction of two cysteines allowed for the incorporation of two molecules of probe. The
bound probe showed an increase in fluorescent intensity with a 20 nm blue shift in probe
emission wavelength.
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